Table 1.
Baseline characteristics of spondyloarthritis (SpA) patients and control group (CG).
| SpA (n = 183) |
CG (n = 183) |
|
|---|---|---|
| Demographics | ||
| Current age, years | 51.2 (12.0) | 51.2 (12.3) |
| Female, sex | 74 (40.4) | 74 (40.4) |
| Caucasian ethnicity | 114 (62.3)b | 80 (43.7) |
| Comorbidities | ||
| Systemic arterial hypertension | 80 (43.7)a | 53 (29.0) |
| Diabetes mellitus | 27 (14.8) | 29 (15.8) |
| Dyslipidemia | 60 (32.8)b | 9 (4.9) |
| Obesity | 58 (31.7) | 44 (23.3) |
| Chronic cardiomyopathy | 6 (3.3) | 3 (1.6) |
| Chronic renal disease | 14 (7.7)b | 0 |
| Current smoking | 9 (4.9)a | 24 (13.1) |
| COPD | 1 (0.5) | 2 (1.1) |
| Asthma | 5 (2.7) | 6 (3.3) |
| Interstitial lung disease | 1 (0.5) | 0 |
| Pulmonary hypertension | 2 (1.1) | 0 |
| Hepatic disease | 15 (8.6)b | 1 (0.5) |
| Current cancer | 1 (0.5) | 0 |
| Stroke | 1 (0.5) | 0 |
| Current tuberculosis | 1 (0.5) | 0 |
| SpA | ||
| AxSpA | 100 (54.6) | – |
| PsA | 83 (45.4) | – |
| Disease activity | ||
| ASDAS-CRP | 2.0 (1.1) | – |
| BASDAI | 2.3 (2.0) | – |
| DAPSA | 13.9 (14.5) | – |
| PASI | 2.9 (4.5) | – |
| Current therapy | ||
| Prednisone | 15 (8.2) | – |
| Prednisone dose, mg | 8 (6.0) | – |
| NSAID | 74 (40.4) | – |
| Sulfasalazine | 41 (22.4) | – |
| Immunosuppressive drugs | 74 (40.4) | – |
| Methotrexate | 53 (29.0) | – |
| Leflunomide | 29 (15.8) | – |
| Biologic therapy | 106 (57.9) | – |
| TNFi | 73 (39.9) | – |
| Adalimumab | 29 (15.3) | – |
| Infliximab | 26 (14.2) | – |
| Etanercept | 12 (6.6) | – |
| Golimumab | 8 (4.4) | – |
| Certolizumab | 2 (1.1) | – |
| Secukinumab | 27 (14.8) | – |
| Ustekinumab | 3 (1.6) | – |
Results are expressed in mean (SD) and n (%). COPD: chronic obstructive pulmonary disease; ASDAS-CRP: ankylosing spondylitis disease activity score-C reactive protein; BASDAI: Bath ankylosing spondylitis disease activity index; DAPSA: disease activity in psoriatic arthritis; PASI: psoriasis area severity index; NSAID: non-steroidal anti-inflammatory drugs; TNFi: tumor necrosis factor inhibitor; AxSpA: axial spondyloarthritis (non-radiographic spondyloarthritis and ankylosing spondylitis); PsA: psoriatic arthritis.
a
For comparisons between SpA patients and CG: P < 0.01.
b
For comparisons between SpA patients and CG: P < 0.001.